Find a Trial

Trial Summary


Protocol No.CTO-S1801
StatusOPEN TO ACCRUAL
Principal InvestigatorLogan, Theodore
ScopeLocal
PhasePhase II
Age GroupAdult
TitleA PHASE II RANDOMIZED STUDY OF ADJUVANT VERSUS NEOADJUVANT MK-3475 (PEMBROLIZUMAB) FOR CLINICALLY DETECTABLE STAGE III-IV HIGH RISK MELANOMA
DescriptionThis phase II trial studies how pembrolizumab works before and after surgery in treating patients with stage III-IV high-risk melanoma. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab before and after surgery may work better in treating melanoma.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:
  • Men and Women 18 and older
  • Patients must not have an active infection requiring systemic therapy.
For a full list of participation criteria, please visit clinicaltrials.gov.
Applicable Disease SitesMelanoma, Skin
Participating InstitutionsIndiana University (IU)
    Treatment TypeTreatment
    ContactPhone: (317) 278-5632
    Email: iutrials@iu.edu